Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LESLIE BRYAN FORGOSH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154305738
CMS profile
278624
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,618.47

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,165.59 3
Food and Beverage $452.88 7

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LESLIE BRYAN FORGOSH

NPI 1154305738 · CMS profile ID 278624

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1154305738?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,618.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $140.2710/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092540772 CMS
Edwards Lifesciences Corporation $22.6109/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138847131 CMS
Janssen Research & Development, LLC $20.0003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588383 CMS
Janssen Research & Development, LLC $289.7303/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588385 CMS
Janssen Research & Development, LLC $20.0003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588387 CMS
Janssen Research & Development, LLC $60.0003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588389 CMS
Janssen Research & Development, LLC $40.0003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588391 CMS
Janssen Research & Development, LLC $150.0003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588393 CMS
Janssen Research & Development, LLC $124.8603/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588395 CMS
Janssen Research & Development, LLC $751.0002/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588381 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.62 2
PY2020 $13.55 1
PY2022 $3,264.08 18
PY2023 $2,534.72 16
PY2024 $1,618.47 10
PY2025 $1,013.54 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,031.09 11
PY2025 Principal investigator $1,145,528.44 27
PY2024 Principal investigator $1,362,432.04 31
PY2023 Recipient $140.82 1
PY2023 Principal investigator $1,104,464.55 33
PY2022 Recipient $3,197.00 1
PY2022 Principal investigator $739,768.96 53
PY2021 Recipient $4,441.01 1
PY2021 Principal investigator $667,326.41 59
PY2020 Recipient $6,717.97 2
PY2020 Principal investigator $475,435.63 71
PY2019 Principal investigator $661,892.22 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Kowa Research Institute, Inc. $446.40 12/21/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771714730
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 12/16/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838454477
Principal investigator 1 Kowa Research Institute, Inc. $2,392.20 12/14/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771714728
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $416.00 12/07/2021 Non-covered Recipient Entity
Fairview Health Services
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789147559
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 12/03/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF MINNESOTA MEDICAL CTR
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 848740373
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 12/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838451757
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 12/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838451765
Principal investigator 1 Kowa Research Institute, Inc. $7,273.80 12/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771714726
Principal investigator 1 Kowa Research Institute, Inc. $3,020.40 10/26/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771714724
Principal investigator 1 Esperion Therapeutics, Inc. $1,371.00 10/21/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838437420
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 10/21/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838437429
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 10/21/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838437437
Principal investigator 1 Amryt Pharma Holdings Ltd $147.70 10/20/2021 Non-covered Recipient Entity
HealthEast Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 831208299
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,641.00 09/28/2021 Non-covered Recipient Entity
Fairview Health Services
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789148471
Principal investigator 1 Kowa Research Institute, Inc. $4,113.00 09/24/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771713760
Principal investigator 1 Amryt Pharma Holdings Ltd $3,000.00 09/22/2021 Non-covered Recipient Entity
HealthEast Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 831208293
Principal investigator 1 Kowa Research Institute, Inc. $2,350.80 08/23/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771713758
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 08/19/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429843
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $14,943.00 07/28/2021 Non-covered Recipient Entity
Fairview Health Services
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789148031
Principal investigator 1 Kowa Research Institute, Inc. $9,108.00 07/26/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771713756
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 07/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838425303
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 07/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838425311
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 07/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838425319
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 07/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838425327
Principal investigator 1 SANOFI US SERVICES INC. $10,036.00 07/19/2021 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 838664047
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,750.00 06/30/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) No dispute reported 06/30/2026 800629336
Principal investigator 1 Kowa Research Institute, Inc. $3,722.40 06/24/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771711618
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 06/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420855
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 06/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838412925
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 06/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838412933
Principal investigator 1 Amgen Inc. $30,860.00 05/25/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20160250-FOURIER OLE (Ph 4) No dispute reported 06/30/2026 830976387
Principal investigator 1 Kowa Research Institute, Inc. $4,442.40 05/24/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771711616
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,720.29 05/15/2021 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 800629075
Principal investigator 1 Amryt Pharma Holdings Ltd $147.70 05/05/2021 Non-covered Recipient Entity
HealthEast Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 831208067
Principal investigator 1 Kowa Research Institute, Inc. $3,996.00 04/26/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771711614
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 04/23/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838409297
Principal investigator 1 Kowa Research Institute, Inc. $500.00 04/06/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771711612
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,896.90 03/25/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 855441059
Principal investigator 1 Amgen Inc. $17,397.00 03/24/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20170625-VESALIUS - CV No dispute reported 06/30/2026 830976997
Principal investigator 1 Kowa Research Institute, Inc. $5,445.00 03/23/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771712562
Principal investigator 1 AKEBIA THERAPEUTICS INC $70.00 03/22/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 855441053
Principal investigator 1 Amgen Inc. $42,513.64 03/22/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20170625-VESALIUS - CV No dispute reported 06/30/2026 830976999
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 03/19/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400373
Principal investigator 1 AKEBIA THERAPEUTICS INC $708.00 03/18/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0015 No dispute reported 06/30/2026 855441041
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,088.00 03/11/2021 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES CLCZ696D2301
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470041
Principal investigator 1 AKEBIA THERAPEUTICS INC $418.05 03/10/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
AKB-6548-CI-0014 No dispute reported 06/30/2026 855441011
Principal investigator 1 Kowa Research Institute, Inc. $5,403.60 03/01/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771712560
Principal investigator 1 Amgen Inc. $132,594.66 02/23/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20160250-FOURIER OLE (Ph 4) No dispute reported 06/30/2026 830976393
Principal investigator 1 Eli Lilly and Company $3,221.31 02/22/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 819459827
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 02/19/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394343
Principal investigator 1 Esperion Therapeutics, Inc. $359.00 02/19/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394351
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 02/19/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394359
Recipient Eli Lilly and Company $4,441.01 02/17/2021 Covered Recipient Physician THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 819446363
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,610.29 02/11/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 826471637
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,300.00 01/28/2021 Non-covered Recipient Entity
HEALTH EAST OSTEOPOROSIS CARE
Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease No dispute reported 06/30/2026 800632395
Principal investigator 1 Novartis Pharmaceuticals Corporation $439.67 01/27/2021 Non-covered Recipient Entity
HEALTHEAST PAIN CLINIC
HPS-4/TIMI 65/ORION-4: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL ASSESSING THE EFFECTS OF INCLISIRAN ON CLINICAL OUTCOMES AMONG PEOPLE WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 800629347
Principal investigator 1 Kowa Research Institute, Inc. $6,422.40 01/26/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 771712558
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 01/25/2021 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388869
Principal investigator 1 Amgen Inc. $1,196.00 01/20/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
20170625-VESALIUS - CV No dispute reported 06/30/2026 830977001
Principal investigator 1 Eli Lilly and Company $245,553.00 01/05/2021 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 819457691